Comparative Pharmacology
Head-to-head clinical analysis: BREATHTEK UBT FOR H PYLORI versus PYLORI CHEK BREATH TEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREATHTEK UBT FOR H PYLORI versus PYLORI CHEK BREATH TEST.
BREATHTEK UBT FOR H-PYLORI vs PYLORI-CHEK BREATH TEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREATHTEK UBT is a 13C-urea breath test that detects Helicobacter pylori infection. The patient ingests 13C-labeled urea; if H. pylori is present, its urease enzyme hydrolyzes urea to 13CO2, which is absorbed and exhaled, allowing detection by mass spectrometry or infrared spectroscopy.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
75 mg of 13C-urea oral powder dissolved in 75 mL water, administered once after a baseline breath sample; a second breath sample is collected 30 minutes after dosing.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
None Documented
None Documented
13C-urea has a plasma half-life of approximately 0.5–1 hour. The 13CO2 exhaled peak occurs at 20–30 minutes, reflecting rapid urease hydrolysis. The terminal half-life is not clinically relevant as the breath test relies on early exhalation kinetics.
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
BreathTek UBT (13C-urea) is metabolized by H. pylori urease to 13CO2, which is exhaled. Unmetabolized urea is renally excreted; renal elimination of unchanged 13C-urea accounts for approximately 20-30% of the administered dose, with the remainder exhaled as 13CO2 within 60 minutes. Fecal/biliary excretion is negligible.
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Category C
Category C
Diagnostic Agent
Diagnostic Agent